NCT07353554Not yet recruiting
Application Study of 68Ga-NOTA-BCMA Nanoantibody Imaging in Multiple Myeloma
Source: ClinicalTrials.gov · Last updated 20 Jan 2026
Brief summary (registry, in English)
This study intends to employ 68Ga-NOTA-BCMA nanobody PET/CT imaging in patients with multiple myeloma to evaluate the feasibility of this technique for myeloma assessment, analyze the correlation between 68Ga-NOTA-BCMA nanobody uptake intensity and disease staging, tumor burden, and prognosis, explore its value in assessing treatment response and predicting early relapse, and compare its detection rate for myeloma lesions with that of 18F-FDG PET/CT. The results of this study may provide a more sensitive and specific imaging diagnostic method for patients with multiple myeloma and offer a basis for the individualized selection of future BCMA-targeted therapies. This study has been approved by the Ethics Committee of Peking Union Medical College Hospital.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 10 Sept 2025
- Start date
- 1 Feb 2026
- Primary completion date
- 1 Feb 2028
- Lead sponsor
- Peking Union Medical College Hospital
- Diseases
- Multiple myeloma
- NCT number
- NCT07353554
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 1 Feb 2026 to the primary completion date, 1 Feb 2028
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Patients with claustrophobia or other psychiatric disorders, or poor compliance that may compromise their ability to cooperate with the study procedures.
Other
- Severely abnormal liver and kidney function
- Women who are planning pregnancy, are pregnant, or are breastfeeding, as well as those with childcare plans during the study period; subjects of childbearing potential must use effective contraceptive measures throughout the study.
- Individuals unable to lie flat for 30 minutes.
- Individuals who decline to participate in this clinical study.
- Other circumstances deemed by the investigator as unsuitable for participation in this clinical trial.
Who the study is looking for
- Newly diagnosed or relapsed MM patients
- Written informed consent obtained and capable of undergoing follow-up.
Age in the registry: 18 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Peking Union Medical College Coordinator of this site? Confirm its status | Beijing | China | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.